Abbott Laboratories

NYSE:ABT 株式レポート

時価総額：US$158.1b

Abbott Laboratories 将来の成長

Future 基準チェック /26

Abbott Laboratories利益と収益がそれぞれ年間12.6%と8.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.4% 12.6%なると予測されています。

主要情報

12.6%

収益成長率

12.58%

EPS成長率

Medical Equipment 収益成長16.1%
収益成長率8.2%
将来の株主資本利益率22.39%
アナリストカバレッジ

Good

最終更新日28 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 02

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.
ナラティブの更新 • May 12

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.
Seeking Alpha • May 09

Abbott Laboratories Is On Sale, Don't Overlook It

Summary Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak. Litigation over infant formula and Exact Sciences' integration pose risks, but ABT's fundamentals and earnings growth underpin a projected 45% upside by 2027. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 23

ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.
ナラティブの更新 • Apr 09

ABT: AF Portfolio And Dividend Track Record Will Support Future Upside

Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.
ナラティブの更新 • Mar 26

ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside

Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.
ナラティブの更新 • Mar 11

ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside

Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.
ナラティブの更新 • Feb 24

ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside

Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.
ナラティブの更新 • Feb 10

ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside

Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.
ナラティブの更新 • Jan 26

ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential

Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.
ナラティブの更新 • Jan 11

ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside

Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.
分析記事 • Jan 03

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
ナラティブの更新 • Dec 27

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns

Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.
ナラティブの更新 • Dec 12

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside

Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.
ナラティブの更新 • Nov 28

ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside

Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.
ナラティブの更新 • Nov 14

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
分析記事 • Nov 05

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
ナラティブの更新 • Oct 31

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
ナラティブの更新 • Oct 16

Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds

Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.
分析記事 • Sep 15

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...
Seeking Alpha • Apr 16

Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking Alpha
Seeking Alpha • Mar 16

Abbott Laboratories Basking In A Sharp Turn In Sentiment

Summary Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk. Fourth quarter results showed 9% organic revenue growth, with medical devices leading at 14%, and improved profit margins. Abbott's medical device business is executing well, with double-digit growth in structural heart and diabetes, and above-peer results across most of the business. An important legal victory could signal lower overall risk in its infant nutrition litigation, while a lackluster trial result from a rival could re-energize the outlook for TriClip. Valuation is more challenging now, as it takes a pretty aggressive bull-case model to find significant fundamentals-driven upside. Read the full article on Seeking Alpha

業績と収益の成長予測

NYSE:ABT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202858,7049,23010,39112,63718
12/31/202754,8028,1689,43811,44124
12/31/202650,2917,0198,62710,66424
3/31/202645,1346,2527,3789,464N/A
12/31/202544,3286,5007,3959,566N/A
9/30/202543,84313,9756,9179,119N/A
6/30/202543,10913,9776,7759,037N/A
3/31/202542,34413,5006,6578,950N/A
12/31/202441,95013,4006,3518,558N/A
9/30/202441,2175,7616,4868,728N/A
6/30/202440,7255,5465,6547,900N/A
3/31/202440,3265,6084,9237,143N/A
12/31/202340,1095,7005,0597,261N/A
9/30/202339,9595,1424,4926,549N/A
6/30/202340,2265,1405,4887,452N/A
3/31/202341,5055,7856,8238,659N/A
12/31/202243,6536,9057,8049,581N/A
9/30/202245,0307,8578,54110,322N/A
6/30/202245,5488,5208,46810,243N/A
3/31/202244,5147,6958,1529,961N/A
12/31/202143,0757,0428,64810,533N/A
9/30/202142,3087,2089,31411,264N/A
6/30/202140,2336,3438,64410,629N/A
3/31/202137,3385,6937,6099,823N/A
12/31/202034,6084,4495,7247,901N/A
9/30/202032,2213,3464,5876,519N/A
6/30/202031,4443,0734,5646,401N/A
3/31/202032,0953,5394,4766,139N/A
12/31/201931,9043,666N/A6,136N/A
9/30/201931,3553,272N/A5,485N/A
6/30/201930,9352,867N/A5,720N/A
3/31/201930,7232,582N/A5,904N/A
12/31/201830,5782,319N/A6,300N/A
9/30/201830,402802N/A6,175N/A
6/30/201829,575812N/A5,997N/A
3/31/201828,445365N/A6,104N/A
12/31/201727,390344N/A5,570N/A
9/30/201725,1341,971N/A5,100N/A
6/30/201723,6071,055N/A4,312N/A
3/31/201722,3031,384N/A3,870N/A
12/31/201620,8531,056N/A3,203N/A
9/30/201620,708989N/A2,861N/A
6/30/201620,5561,939N/A2,839N/A
3/31/201620,3932,124N/A2,871N/A
12/31/201520,4052,586N/A2,966N/A
9/30/201520,5732,523N/A3,376N/A
6/30/201520,5022,365N/A3,382N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABTの予測収益成長率 (年間12.6% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: ABTの収益 ( 12.6% ) US市場 ( 17.1% ) よりも低い成長が予測されています。

高成長収益: ABTの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ABTの収益 ( 8.2% ) US市場 ( 11.9% ) よりも低い成長が予測されています。

高い収益成長: ABTの収益 ( 8.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABTの 自己資本利益率 は、3年後には高くなると予測されています ( 22.4 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/05 12:13
終値2026/06/05 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Abbott Laboratories 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。51

アナリスト機関
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays